We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
NUCALA GlaxoSmithKline Australia Pty Ltd
Product name
NUCALA
Accepted date
Apr-2025
Active ingredients
Mepolizumab
Proposed indication
NUCALA (mepolizumab) is used as an additional treatment for adults with chronic obstructive pulmonary disease (COPD; a chronic lung disease that causes breathing difficulties). It is for a type of COPD where the lungs have high levels of eosinophils (a type of blood cell that can cause allergies or asthma)
Application type
C (new indication)
Publication date
Apr-2025